Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARN_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PARN_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000989625 | Oral cavity | EOLP | positive regulation of catabolic process | 118/2218 | 492/18723 | 2.32e-14 | 9.26e-12 | 118 |
GO:003133125 | Oral cavity | EOLP | positive regulation of cellular catabolic process | 106/2218 | 427/18723 | 4.63e-14 | 1.63e-11 | 106 |
GO:006101323 | Oral cavity | EOLP | regulation of mRNA catabolic process | 55/2218 | 166/18723 | 3.70e-13 | 1.11e-10 | 55 |
GO:000640124 | Oral cavity | EOLP | RNA catabolic process | 77/2218 | 278/18723 | 3.92e-13 | 1.12e-10 | 77 |
GO:000641726 | Oral cavity | EOLP | regulation of translation | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:004348823 | Oral cavity | EOLP | regulation of mRNA stability | 50/2218 | 158/18723 | 2.91e-11 | 4.15e-09 | 50 |
GO:000640323 | Oral cavity | EOLP | RNA localization | 57/2218 | 201/18723 | 1.62e-10 | 1.68e-08 | 57 |
GO:004348723 | Oral cavity | EOLP | regulation of RNA stability | 51/2218 | 170/18723 | 1.63e-10 | 1.68e-08 | 51 |
GO:190331323 | Oral cavity | EOLP | positive regulation of mRNA metabolic process | 40/2218 | 118/18723 | 2.69e-10 | 2.45e-08 | 40 |
GO:003465523 | Oral cavity | EOLP | nucleobase-containing compound catabolic process | 89/2218 | 407/18723 | 5.47e-09 | 2.92e-07 | 89 |
GO:003133025 | Oral cavity | EOLP | negative regulation of cellular catabolic process | 64/2218 | 262/18723 | 9.72e-09 | 4.77e-07 | 64 |
GO:003304422 | Oral cavity | EOLP | regulation of chromosome organization | 50/2218 | 187/18723 | 1.80e-08 | 7.94e-07 | 50 |
GO:000989525 | Oral cavity | EOLP | negative regulation of catabolic process | 73/2218 | 320/18723 | 2.07e-08 | 8.84e-07 | 73 |
GO:004670023 | Oral cavity | EOLP | heterocycle catabolic process | 93/2218 | 445/18723 | 2.61e-08 | 1.08e-06 | 93 |
GO:004427023 | Oral cavity | EOLP | cellular nitrogen compound catabolic process | 92/2218 | 451/18723 | 1.01e-07 | 3.45e-06 | 92 |
GO:000095623 | Oral cavity | EOLP | nuclear-transcribed mRNA catabolic process | 33/2218 | 112/18723 | 4.21e-07 | 1.19e-05 | 33 |
GO:006101423 | Oral cavity | EOLP | positive regulation of mRNA catabolic process | 28/2218 | 87/18723 | 4.26e-07 | 1.19e-05 | 28 |
GO:001943923 | Oral cavity | EOLP | aromatic compound catabolic process | 92/2218 | 467/18723 | 5.23e-07 | 1.40e-05 | 92 |
GO:005105222 | Oral cavity | EOLP | regulation of DNA metabolic process | 75/2218 | 359/18723 | 5.81e-07 | 1.53e-05 | 75 |
GO:000072322 | Oral cavity | EOLP | telomere maintenance | 36/2218 | 131/18723 | 8.39e-07 | 2.10e-05 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARN | SNV | Missense_Mutation | rs766730789 | c.1416N>C | p.Gln472His | p.Q472H | O95453 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARN | insertion | Frame_Shift_Ins | novel | c.244_245insGGTTT | p.Lys82ArgfsTer5 | p.K82Rfs*5 | O95453 | protein_coding | | | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
PARN | insertion | Nonsense_Mutation | novel | c.243_244insGAGACAGACAGACAGATATGAGAACATG | p.Lys82GlufsTer7 | p.K82Efs*7 | O95453 | protein_coding | | | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
PARN | SNV | Missense_Mutation | | c.1805N>T | p.Ser602Leu | p.S602L | O95453 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PARN | SNV | Missense_Mutation | novel | c.82N>C | p.Asp28His | p.D28H | O95453 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
PARN | SNV | Missense_Mutation | novel | c.1504N>C | p.Glu502Gln | p.E502Q | O95453 | protein_coding | tolerated(0.07) | possibly_damaging(0.645) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
PARN | insertion | Frame_Shift_Ins | novel | c.195_196insAGGAT | p.Leu66ArgfsTer21 | p.L66Rfs*21 | O95453 | protein_coding | | | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
PARN | SNV | Missense_Mutation | | c.1423N>C | p.Trp475Arg | p.W475R | O95453 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARN | SNV | Missense_Mutation | novel | c.211N>A | p.Leu71Ile | p.L71I | O95453 | protein_coding | deleterious(0.01) | possibly_damaging(0.716) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARN | SNV | Missense_Mutation | | c.1557G>T | p.Glu519Asp | p.E519D | O95453 | protein_coding | tolerated(0.24) | benign(0.006) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |